linjc16/ctgov huggingface dataset:
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Study Overview
=================
Brief Summary
-----------------
The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Detailed Description
-----------------
Objectives: To identify Measles IgG titre in SARS-COV2 infected patients . correlate level of Measles IgG titre with the clinical severity of COVID-19 disease. Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection Criteria: Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate & severe) All patients with confirmed COVID 19 confirmed by positive PCR . . Any age or gender. Exclusion criteria: - Any patient refusing to be involved in the study. Methods: Informed consent will be taken from each subject Full clinical examination. Evaluation of Measles Antibody Titer: The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin). - Anonymous data will be retrieved from the admitted patients' files, such as: CBC, CRP, AST, ALT, ESR, Serum ferritin & SARS CoV 2 RNA PCR swab results. Chest X ray and/or CT chest.

Official Title
-----------------
Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Conditions
-----------------
Coronavirus (COVID-19)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with confirmed COVID 19. Any age or gender Exclusion Criteria: - Any patient refusing to be involved in the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>mild | |
| B<br>moderate | |
| C<br>severe | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Viral clearance | Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital | 6 months |
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Study Overview
=================
Brief Summary
-----------------
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Official Title
-----------------
A Phase 2, Open Label Study of AT-101 in Combination With Rituximab in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia

Conditions
-----------------
Chronic Lymphocytic Leukemia

Intervention / Treatment
-----------------
* Drug: AT-101


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of CLL as defined by the NCI-working group Previous treatment with standard systemic chemotherapy or immunotherapy. Disease progression or relapse after treatment. Indication for treatment as defined by the NCI Working Group Guidelines (Cheson, 1996) ECOG performance status ≤ 2 Adequate liver and renal and bone marrow function Exclusion Criteria: Treatment of CLL with chemotherapy, monoclonal antibody or radiotherapy within 60 days prior to entering the study. Acute toxicities from prior therapy must have resolved to Grade ≤ 1. Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD) Active secondary malignancy or history of other malignancy within the last five years Active symptomatic fungal, bacterial and/or viral infection including active HIV or viral hepatitis (A, B or C). Patients who are contraindicated for treatment with rituximab Diagnosis of prolymphocytic leukemia, hairy cell leukemia, leukemic phase of non-Hodgkin's lymphoma, or other non-B-CLL B-cell malignancy; T-CLL or other T-cell malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: AT-101<br>* 80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of AT-101 in combination with rituximab |  | 5 months for each patient; 20 months entire study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Preliminary efficacy of AT-101 in combination with rituximab |  | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AT101, AT-101, cancer, lymphoctic, lukemia, Rituximab
The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney

Study Overview
=================
Brief Summary
-----------------
Measurement of reactive oxygen species production and antioxidant system status before and directly after reperfusion of the transplanted kidney and influence of oxidant stress on kidney function in 2 and 6 weeks.

Detailed Description
-----------------
Oxidative stress is one of the most important factors in ischaemia-reperfusion injury to the transplanted organ. In kidney transplant recipients following factors were measured: glutathione level, activities of glutathione peroxidase (GSH-PX), catalase (CAT) and superoxide dismutase (SOD) and superoxide anion production by granulocytes in whole blood without and after the stimulation with zymosan. Blood was sampled from peripheral vein (before reperfusion) and directly from renal vein (5 and 15 minutes after reperfusion). Transplanted kidney function was evaluated by the incidence and length of Delayed Graft Function and serum creatinine level in 2 and 6 weeks after transplantation.

Official Title
-----------------
The Role of Reactive Oxygen Species in Ischaemia-Reperfusion Injury of the Transplanted Kidney

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Behavioral: Oxidative stress in kidney transplant recipients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: consecutive patients accepted for and undergoing cadaveric kidney transplantation Exclusion Criteria: no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Oxidative stress in kidney transplant recipients|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kidney transplantation, Reperfusion injury
Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome

Study Overview
=================
Brief Summary
-----------------
Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The establishment of a cohort study on the therapeutic effect of gamma globulin in Guillain-barre Syndrome is beneficial to the diagnosis of the disease and to the understanding of the natural course of the disease and the efficacy of drug treatment.

Official Title
-----------------
An Observational Cohort Study on the Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome

Conditions
-----------------
Guillain-barre Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet the Brighton Guillain-Barre Syndrome diagnosis criteria in 2014; Age ≥18; Patients with AIDP, AMAN and AMSAN; 5. IVIG was treated within 2 weeks of onset; 6. GBS disability scale>2; 6. Cooperate with patients who were followed up for 180 days and sign the informed consent; Exclusion criteria: Age <18; Pregnant or nursing women; Patients with Chronic inflammatory demyelinating multiple peripheral neuropathy; Combined with other types of immune system diseases; Accept drugs that affect the function of the immune system within 5 or 3 months; Concomitant neoplastic diseases. The patient or guardian refused to sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| GBS disability score | GBS disability scale ( Guillain-Barré syndrome disability scale) was defined as follows: 0: healthy state; 1: minor symptoms and capable of running; 2: able to walk 5 meters or more without assistance but unable to run; 3: able to walk 5 meters across an open space with help; 4: bedridden or chair-bound; 5: requiring assisted ventilation for at least part of the day; 6: dead | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory function | whether mechanical ventilation is required | 6 months |
Risk Factors for Postoperative Nausea/Vomiting

Study Overview
=================
Brief Summary
-----------------
General anesthetic technique plays a key role in most surgical procedures. This technique has some complications especially postoperative nausea/vomiting (PONV). This complication can lead to serious problems. Department of Anesthesiology has developed and implemented a PONV prophylaxis guideline for high risk PONV patients but PONV still remains.

Detailed Description
-----------------
Objective: To identify risk factors for PONV after implementation of PONV prophylaxis guideline. Methods: This will be a retrospective analytic study. Relevant clinical data from medical records of adult patients undergoing general anesthesia in Srinagarind Hospital from November 2014 to February 2015 will be used to identify relevant risk factors.

Official Title
-----------------
Risk Factors for Postoperative Nausea/Vomiting After Implementation of Prophylaxis Guideline for High Risk Patients

Conditions
-----------------
Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Procedure: General anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA classification I-III Exclusion Criteria: Incomplete or illegible medical records Patients who underwent cardio-thoracic surgery Patient who had chronic treatment with antiemetic drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Postoperative nausea and vomiting<br>Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting | Procedure: General anesthesia<br>* Patients undergoing general anesthesia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative nausea and vomiting |  | through study completion, an average of 24 hours |
The Role of Convex Skin Barrier in Prevention of Peristomy Skin Complication-Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The incidence of peristomy skin complication ranges from 15% to 65%. It is a serious issue and problem for patients care.The type of skin barrier is associated with peristomy skin complication. How to choose suitable skin barrier is important.

Official Title
-----------------
The Role of Convex Skin Barrier in Prevention of Peristomy Skin Complication-Randomized Controlled Trial

Conditions
-----------------
Stoma Colostomy, Stoma Ileostomy

Intervention / Treatment
-----------------
* Device: convex skin barrier


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>20 Receive colostomy or ileostomy Agree to join the trial and sign the informed consent form Exclusion Criteria: Liver cirrhosis Renal insufficiency Severe malnutrition Unstable vital sign Not suitable after evaluation by Principal Investigator

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: not convex skin barrier<br>no intervention | |
| Experimental: convex skin barrier<br>intervention | Device: convex skin barrier<br>* Total 300 patients and grouping in 1:1 ratio.(1)peristomy skin complication (30 mins) (2)life quality stomy care (3-5 mins) (3)stomy appliance satisfaction (3-5 mins)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peristomy skin complication rate | peristomy skin complication rate | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| (2) life quality stomy care questionnaire | life quality stomy care questionnaire | one month | 
| (3) stomy appliance satisfaction questionnaire | stomy appliance satisfaction questionnaire | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peristomy skin complication, convex skin barrier
Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The study is designed to evaluate effects of NSAIDs on immune activity inside and close to tumor tissue in patients with colorectal cancer.

Detailed Description
-----------------
Study and control patients are randomized to receive preoperative treatment with indomethacin or celecoxib compared to sham treatment.Tumor biopsies are taken at operation and used for analyses of tumor immunity and gene expression.

Official Title
-----------------
Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Drug: Indomethacin, celecoxib, esomeprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Colon carcinoma scheduled for curative operation Exclusion Criteria: Diabetes, steroid medication, liver and kidney impairment

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Drug<br>Treatment with indomethacin or celecoxib | Drug: Indomethacin, celecoxib, esomeprazole<br> <br> |
| Sham Comparator: SHAM<br>Sham treatment | Drug: Indomethacin, celecoxib, esomeprazole<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune reactivity |  | Acute evaluations | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MHC, CTLs, Colon carcinoma, NSAID, Survival
Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the absorption, metabolism and excretion following a single oral dose of [14C]KWA-0711 to healthy male subjects.

Conditions
-----------------
Healthy Male Subject

Intervention / Treatment
-----------------
* Drug: [14C]KWA-0711


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who are male, caucasian, and between 35 and 55 years of age, inclusive. Subjects who have a body mass index (BMI) between 18.5 and 30.0 kg/m2, inclusive. Subjects who have a body weight between 50 and 100 kg, inclusive. Subjects must have regular bowel movements. Exclusion Criteria: Subjects who have an abnormality in heart rate, blood pressure , temperature or 12-lead ECG. Subjects who are still participating in a clinical study or who have participated in a clinical study involving administration of an investigational drug in the 3 months prior to dose administration. Subjects who have had a clinically significant illness within 4 weeks of dose administration as determined by the Investigator. Subjects who have any clinically significant abnormal laboratory safety findings. Subjects who have had an X ray or who have participated in any clinical trial involving a radiolabelled investigational product or have been exposed to radiolabelled substances within 12 months prior to dose administration.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: [14C]KWA-0711<br> | Drug: [14C]KWA-0711<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the plasma concentration-time curve (AUC) of total radioactivity, unchanged drug substance and its major metabolites |  | 240 hours | 
| Maximum observed plasma concentration (Cmax) of total radioactivity, unchanged drug substance and its major metabolites |  | 240 hours | 
| Cumulative radioactivity recovery in urine and feces |  | 240 hours | 
| Profiles of metabolites in plasma, urine and faeces |  | 240 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events |  | 240 hours |
Outcome of ECMO and CRRT.

Study Overview
=================
Brief Summary
-----------------
Background: Although acute kidney injury (AKI) is a frequent complication in patients receiving extracorporeal membrane oxygenation (ECMO), and the CRRT impact is widely studied. The incidence of simultaneous use of ECMO and CRRT remain unclear. Objective: The investigatore conducted this retrospective study to define the incidence of concomitant CRRT with ECMO therapy and to determine the overall impact of this strategy on patient outcomes such as mortality and renal recovery. Methods: The investigatore retrospectively analyzed data of patients of all ages, genders and ethnicities, admitted in the intensive care unit of Mohammed VI University Hospital, Oujda, Morocco, on a cumulative period of 2 years (January 2019 - December 2020). Were enrolled in the study patients who benefited from ECMO, and presented an acute kidney injury afterwards, using 'Microsoft Excel' as a software to utilize the information collected from the computerized patient database. 30 patients were included in the final study.

Official Title
-----------------
Outcome of ECMO and CRRT, Experience of Hospital University MED VI, Oujda, Morocco.

Conditions
-----------------
Incidence of CRRT With ECMO Therapy, Mortality, and Renal Recovery

Intervention / Treatment
-----------------
* Other: supervision the Kidney fonction on ECMO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: benefited from ECMO . presented an acute kidney injury afterwards Exclusion Criteria: patients who developed AKI before benefitting from ECMO and/or missing data
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ECMO and AKI<br> | Other: supervision the Kidney fonction on ECMO<br>* patients who benefited from ECMO, and presented an acute kidney injury afterwards<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ecmo and severe AKI requiring CRRT | 2 groups of patient was identified on this study : first ones are how developped aki and needek CRRT , 2nd are those who developped aki without CRRT | through study completion, an average of 24 mounths | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AKI, COVID, CRRT, Ecmo